Open an account

Protara Therapeutics

TARA · NASDAQ

$2.56+$0.23 (+9.87%)TodayMarket closed ·
Prev close $2.33

About TARA

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 46 full-time employees. The company went IPO on 2014-10-22. The firm's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin, as well as a Phase II trial in pediatric patients with LMs. TARA-002 is a first-in-class TLR2/NOD2 agonist and novel immunopotentiator derived from inactivated Streptococcus pyogenes. Additionally, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes.

Employees
46
Headquarters
New York City, New York
Listed
Oct 22, 2014
Sector
Health Care
Industry
Biotechnology
Website
protaratx.com

TARA key statistics

Market cap
151.28M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.65M
Volume
1.50M
Open price
$2.34
High today
$2.58
Low today
$2.33
52 Week high
$7.82
52 Week low
$2.30

Protara Therapeutics (TARA) at a glance

As of Oct 20, 2026, Protara Therapeutics (TARA) shares are priced at $2.56, giving the company a market cap of 151.28M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.33 and $2.58. The current price is 9.9% above the day's low and 0.6% below its high.

Volume so far is 1.50M shares, in line with the average of 1.65M shares a day.

Over the past year Protara Therapeutics has ranged from $2.30 to $7.82, and now sits 5% of the way up that range.

Protara Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.36 per share against an estimate of -$0.3322.

The average analyst price target is $26.18, 922.7% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $26.18
Low
$20.20
Now
$2.56
High
$31.50

TARA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 18.8% on average.

  1. Q3 FY24: reported -$0.50 per share against an estimate of -$0.5304
  2. Q4 FY24: reported -$0.49 per share against an estimate of -$0.5763
  3. Q1 FY25: reported -$0.29 per share against an estimate of -$0.461
  4. Q2 FY25: reported -$0.35 per share against an estimate of -$0.4131
  5. Q3 FY25: reported -$0.31 per share against an estimate of -$0.3917
  6. Q4 FY25: reported -$0.37 per share against an estimate of -$0.3315
  7. Q1 FY26: reported -$0.31 per share against an estimate of -$0.3818
  8. Q2 FY26: reported -$0.36 per share against an estimate of -$0.3322

TARA news

  • Vandana Singh

    Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Press releaseGlobe Newswire

    Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Vandana Singh

    What's Going On With Protara Therapeutics Stock Wednesday?

  • Press releaseBusiness Wire

    Catalio Capital Management Raises Over $400M to Invest in Innovative Healthcare Companies in its Fourth Venture Fund

  • Press releaseGlobe Newswire

    Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Similar companies

Companies in the same industry as Protara Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.